Evidence map›Paper›PMID 22044855›Full record

Trial reportHIV clinical trials

Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis.

S Krishnan, K Wu, M Smurzynski, R J Bosch, C A Benson, A C Collier, M K Klebert, J Feinberg, S L Koletar, ALLRT/A5001 Team

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in HIV clinical trials. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014
    Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Frailty, Neurocognitive Impairment, or Both in Predicting Poor Health Outcomes Among Adults Living With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Observational
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

S KrishnanCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, USA. krishnan@sdac.harvard.edu
K Wu
M Smurzynski
R J Bosch
C A Benson
A C Collier
M K Klebert
J Feinberg
S L Koletar
ALLRT/A5001 Team
Cancer Research And Biostatistics · USHarvard University · USThe Ohio State University · USUniversity of California, San Diego · USUniversity of Cincinnati Medical Center · USUniversity of Washington · USWashington University in St. Louis · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
STATISTICAL AND DATA MANAGEMENT CENTERU01AI038855 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 1996 to 2006
$78.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
The Ohio State University AIDS Clinical Trials UnitU01AI069474 · NIAID · OHIO STATE UNIVERSITY · PI KOLETAR, SUSAN L · 2007 to 2011
$9.4M
WASHINGTON UNIVERSITY AIDS CLINICAL TRIALS UNITU01AI069495 · NIAID · WASHINGTON UNIVERSITY · PI CLIFFORD, DAVID B · 2007 to 2011
$7.7M
UW Clinical HIV Integrated Research ProgramU01AI069434 · NIAID · UNIVERSITY OF WASHINGTON · PI COLLIER, ANN CORNWALL · 2007 to 2011
$5.6M
The Ohio State University AIDS Clinical Trials UnitUM1AI069474 · NIAID · OHIO STATE UNIVERSITY · PI KOLETAR, SUSAN L · 2012 to 2013
$3.0M
WASHINGTON UNIVERSITY AIDS CLINICAL TRIALS UNITUM1AI069495 · NIAID · WASHINGTON UNIVERSITY · PI CLIFFORD, DAVID B · 2012 to 2013
$2.9M
NIAID NIH HHS AI069474NIAID NIH HHS AI069495NIAID NIH HHS AI 38855NIAID NIH HHS AI 38858NIAID NIH HHS AI 68634NIAID NIH HHS AI 68636NIAID NIH HHS AI 69434NIAID NIH HHS P30 AI050410NIAID NIH HHS U01 AI038855NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI069434NIAID NIH HHS U01 AI069474NIAID NIH HHS U01 AI069495NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069434NIAID NIH HHS UM1 AI069474NIAID NIH HHS UM1 AI069495
6 · The paper itself

Abstract

purposeExamine incidence and factors associated with loss to follow-up (LTFU) in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) cohort.

methodALLRT is a prospective cohort of HIV-infected persons randomized to antiretroviral (ARV) regimens/strategies in ACTG trials and followed long-term after the trial ends. Person-years were calculated from ALLRT entry until loss to follow-up (LTFU; defined using off-study reasons or ≥ 3 consecutive missed visits), death/ severe debilitation/site closures, or June 2009 (censored). Poisson regression was used to examine LTFU factors separately among participants who were ARV naïve or ARV experienced at trial entry.

resultsAmong 4,630 participants (22,524 person-years), 1,140 were lost to follow-up, 237 died, 29 were severely debilitated, and 443 were at sites that closed. The LTFU incidence was 5.5 and 4.2 per 100 person-years among previously ARV-naïve and ARV-experienced participants, respectively. In both groups, age ≤ 50, site location, being off ARVs, and viral load ≥ 400 copies/mL were associated with a higher risk of LTFU. Among ARV-naïve participants, male sex, education <16 years, intravenous drug use, and cigarette smoking were also associated with LTFU.

conclusionKnowledge of differential LTFU can help researchers identify participants at risk of LTFU in longitudinal HIV cohorts and design retention strategies, thereby limiting study bias. The identified factors should be included in inverse probability of weighting models to account for LTFU.

Indexed as

AdultAgedCohort StudiesFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceLongitudinal StudiesMaleMiddle AgedProspective Studies

Identifiers

PMID22044855
PMCPMC3207266
OpenAlexW1968376638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.